drugset

drugset / Trial / NCT03282149

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain

NCT03282149 ↗

Phase 1 Completed 24 enrolled Xalud Therapeutics, Inc.

RandomizedSequentialQuadruple-blindTreatment

Summary

Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain - Dose escalation

Timeline

Start: 2018-03-21
Primary completion: 2019-03-31
Completion: 2019-06-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XT-150	Other / unclassified	—	Other

Indications